Synthetic Polymer Patents (Class 424/486)
-
Patent number: 10584371Abstract: The present invention relates to a method for lyophilizing a composition for multiple target nucleic acid sequence amplification reaction and a lyophilizate prepared by the method. The present method is very effective in lyophilizing a composition containing a high concentration of oligonucleotides. The lyophilizates prepared by the present invention exhibits excellent properties in terms of both sensitivity and specificity, equivalent performance capacity to conventional liquid formulation and furthermore remarkable storage stability. Accordingly, the lyophilizates prepared by the present invention would be very useful in diagnosis.Type: GrantFiled: February 12, 2016Date of Patent: March 10, 2020Assignee: SEEGENE, INC.Inventors: Jong Yoon Chun, Won Jun Oh
-
Patent number: 10568975Abstract: Surface conjugated diamagnetic Chemical Exchange Saturation Transfer (diaCEST) agent carriers and methods of making and using are described herein. The particles are safe alternatives to conventional paramagnetic or superparamagnetic metal-based MRI contrast agents that are often toxic and therefore not biocompatible. The carriers described herein can provide simultaneous monitoring of multiple particle types labeled with ‘multicolor’ diaCEST contrast agents. In some embodiments, the carriers are micro- and/or nanoparticles. In other embodiments, the carriers are liposomes. In some embodiments, the particles and/or liposomes are mucus penetrating. In other embodiments, the particles and/or liposomes are not mucus penetrating.Type: GrantFiled: February 5, 2014Date of Patent: February 25, 2020Assignee: The Johns Hopkins UniversityInventors: Tao Yu, Himatkumar Patel, Kannie M. Y. Chan, Nikita Oskolkov, Michael McMahon, Justin Hanes
-
Patent number: 10568860Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.Type: GrantFiled: August 30, 2007Date of Patent: February 25, 2020Assignees: KOWA CO., LTD., SENTANIRYOUKAIHATSU CO., LTD.Inventor: Kensuke Egashira
-
Patent number: 10561586Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.Type: GrantFiled: May 26, 2016Date of Patent: February 18, 2020Assignee: BEIERSDORF AGInventors: Jonatan Scherer, David Winterstein, Heike Miertsch
-
Patent number: 10559227Abstract: Simulated tissue products and methods involving an enhanced simulated tissue product, the enhanced simulated tissue product formed from a polyvinyl alcohol material having a molecular chain length in a range of at least approximately 7000 vinyl alcohol repeat units; and water, wherein the polyvinyl alcohol material has a preferred molecular chain length in a range of at least approximately 7150 vinyl alcohol repeat units; wherein the aqueous polyvinyl alcohol solution involves an additive, and, wherein the additive involves a plurality of nanoparticles. The simulated tissue products and methods are further useful with multi-metric surgery simulator devices, systems, and methods, such as those for training surgical tasks.Type: GrantFiled: June 2, 2016Date of Patent: February 11, 2020Assignee: Synaptive Medical (Barbados) Inc.Inventors: Timotheus Anton Gmeiner, Fergal Kerins, Gregory Allan Whitton, Kimberly Bojanowski Hoang
-
Patent number: 10538373Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: GrantFiled: May 21, 2019Date of Patent: January 21, 2020Assignee: GW Pharma LimitedInventor: Brian Anthony Whittle
-
Patent number: 10511004Abstract: A non-aqueous electrolyte secondary battery has a positive electrode having a positive electrode active material layer, a negative electrode having a negative electrode active material layer, and an electrolyte layer having an electrolyte solution containing a non-aqueous solvent. At least one of the positive electrode active material layer and the negative electrode active material layer contains an electrode material for a non-aqueous electrolyte secondary battery having a core part including an electrode active material and a shell part including a conductive material in a base material formed by a gel-forming polymer having a liquid absorption rate with respect to the electrolyte solution of 10 to 200%.Type: GrantFiled: January 26, 2015Date of Patent: December 17, 2019Assignee: Nissan Motor Co., Ltd.Inventors: Yuki Kusachi, Yasuhiko Ohsawa, Hiroshi Akama, Hideaki Horie, Yuta Murakami, Kenichi Kawakita, Yusuke Mizuno, Yasuhiro Tsudo, Yasuhiro Shindo
-
Patent number: 10478403Abstract: A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan; and an additive selected from the group consisting of a hydration promoter, a particle adhesion inhibitor, a particle aggregation inhibitor, and combinations thereof. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.Type: GrantFiled: May 3, 2018Date of Patent: November 19, 2019Assignee: Privo Technologies, Inc.Inventors: Manijeh Nazari Goldberg, Brandon LaPorte, Aaron Manzi, Amani Jahjaa
-
Patent number: 10463717Abstract: The invention relates to a composition in the form of an injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: *GpRrGpAaGpC)p ??I characterized in that the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition characterized in that it moreover comprises a prandial insulin.Type: GrantFiled: December 27, 2017Date of Patent: November 5, 2019Assignee: ADOCIAInventors: David Duracher, Gregory Meiffren, Remi Soula
-
Patent number: 10420847Abstract: A system and method for evaluating wound healing dressings, treatments, and other variables. The present invention includes in vitro systems and methods for testing wound dressing materials for bacterial control, moisture control, and surface contact properties. The present invention further includes in vivo systems and methods for testing wound dressings, treatments, and other variables utilizing arrays of wound wells on an experimental subject animal. Wound arrays allow for different wound healing variables to be tested with numerous experimental trials within the same subject animal, giving reliable results and reducing the number of subject animals required for testing.Type: GrantFiled: December 30, 2015Date of Patent: September 24, 2019Assignee: University of Kansas Medical Center Research Institute, Inc.Inventor: David S. Zamierowski
-
Patent number: 10420790Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.Type: GrantFiled: April 27, 2017Date of Patent: September 24, 2019Assignees: University of Washington, GENEVANT SCIENCES GMBHInventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
-
Patent number: 10406335Abstract: Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.Type: GrantFiled: March 29, 2017Date of Patent: September 10, 2019Assignee: TARIS Biomedical LLCInventor: Dennis Giesing
-
Patent number: 10407527Abstract: A novel charge-shifting copolymer is provided comprising a first charge-shifting monomer that is cationic under physiological conditions and which possesses cationic groups that may be converted into anionic groups under physiological conditions, a second monomer comprising at least one primary amine that is not convertible to an anionic group under physiological conditions, and optionally, one or more monomers which are polar uncharged monomers. A hydrogel system incorporating this copolymer, as well as a capsule system, are also provided.Type: GrantFiled: June 3, 2016Date of Patent: September 10, 2019Assignee: McMaster UniversityInventors: Nicholas Burke, Samantha Ros, Harald Stover
-
Patent number: 10401356Abstract: An object of the present invention is to provide an analyte-measuring sensor using a thermoresponsive polymer, which is a novel analyte-measuring sensor capable of quantitatively measuring a target analyte with higher sensitivity. The analyte-measuring sensor of the present invention comprises a labeled particle capable of specifically reacting with a measurement target analyte, a thermoresponsive polymer, a charged substance exhibiting a positive or negative zeta potential in a solution, and a metal particle, and said metal particle is coated with a copolymer of said labeled particle, said charged substance and said thermoresponsive polymer.Type: GrantFiled: September 4, 2013Date of Patent: September 3, 2019Assignee: JNC CORPORATIONInventor: Nobuo Uehara
-
Patent number: 10390533Abstract: Articles having metal, metalloid or non-metal surfaces containing an antimicrobial layer comprising antimicrobial oligomers or polymers are suitable for use in medical devices, sanitary surfaces and other applications. Antimicrobial layers contain an organophosphorus layer deposited on an article surface and antimicrobial oligomers or polymers bonded to the organophosphorus layer.Type: GrantFiled: October 17, 2017Date of Patent: August 27, 2019Assignee: ORTHOBOND CORPORATIONInventor: Randell Clevenger
-
Patent number: 10376590Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.Type: GrantFiled: December 29, 2017Date of Patent: August 13, 2019Assignee: INDIVIOR UK LIMITEDInventors: Eric Dadey, Qi Li, Christopher Lindemann
-
Patent number: 10370656Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.Type: GrantFiled: October 18, 2016Date of Patent: August 6, 2019Assignee: NORTHWESTERN UNIVERSITYInventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos
-
Patent number: 10350112Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: GrantFiled: June 29, 2010Date of Patent: July 16, 2019Assignee: ENOX (ISRAEL) LTD.Inventors: Yossef Av-Gay, David Greenberg
-
Patent number: 10350313Abstract: Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis.Type: GrantFiled: October 14, 2013Date of Patent: July 16, 2019Assignee: GUANGZHOU TONGPENG ZHONGXU PHARMACEUTICAL CO., LTD.Inventor: Pengke Yan
-
Patent number: 10350234Abstract: A composition for use in a nasal application, the composition including an aqueous carrier and a viscosity agent. The viscosity agent is in the range of about 4% to about 15% by weight. The viscosity agent is in solution with the aqueous carrier. The solution of the aqueous carrier and the viscosity agent is configured as a thixotropic composition.Type: GrantFiled: February 28, 2018Date of Patent: July 16, 2019Inventors: Joshua D. Levine, Robert A. Levine
-
Patent number: 10342898Abstract: Embodiments herein include coated medical devices and coatings with salt groups. In an embodiment, a coated medical device is included, the coated medical device including a substrate and a polymeric layer disposed over the substrate. The polymeric layer includes a polymer and has an exterior surface. The coated medical device further includes a plurality of salt groups bonded to the polymer of the polymeric layer and disposed on the exterior surface of the polymeric layer. The salt groups can be the reaction product of a reactive group with an acid or base. In an embodiment, a method of making a medical device is included. Other embodiments are also included herein.Type: GrantFiled: December 12, 2016Date of Patent: July 9, 2019Assignee: Surmodics, Inc.Inventors: David E. Babcock, Joram Slager, Robert W. Hergenrother
-
Patent number: 10335489Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.Type: GrantFiled: October 26, 2015Date of Patent: July 2, 2019Assignee: ADOCIAInventor: Olivier Soula
-
Patent number: 10314937Abstract: Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 ?m to 2000 ?m and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.Type: GrantFiled: September 2, 2015Date of Patent: June 11, 2019Assignee: Endoclot Plus Co., Ltd.Inventors: Xin Ji, Cheng Xing, Heng Zhang
-
Patent number: 10307369Abstract: An antimicrobial polymer for use in an ophthalmic implant, includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic, silicone, vinyl and collagen monomer.Type: GrantFiled: September 8, 2016Date of Patent: June 4, 2019Inventor: Yichieh Shiuey
-
Patent number: 10300175Abstract: A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent—works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialization; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).Type: GrantFiled: September 11, 2015Date of Patent: May 28, 2019Assignee: Heart Research Institute, Ltd.Inventors: Steven G. Wise, Martin K. C. Ng
-
Patent number: 10285948Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.Type: GrantFiled: December 3, 2015Date of Patent: May 14, 2019Assignee: Janssen Pharmaceutica NVInventor: Geert Verreck
-
Patent number: 10286075Abstract: The present invention relates to an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide. An embolization particle of the invention for use in the treatment of cancer in combination with X-ray radiation or proton beam radiation, or use in embolization, is also described. The invention also relates to a process for producing an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide, which process comprises: (i) providing a microparticle; (ii) contacting the microparticle with a plurality of the nanoparticles; and (iii) heating the microparticle and the nanoparticles to form the embolization particle.Type: GrantFiled: April 15, 2016Date of Patent: May 14, 2019Assignee: Oxford University Innovation LimitedInventors: Helen Elizabeth Townley, Rachel Anne Bush
-
Patent number: 10265381Abstract: TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.Type: GrantFiled: December 22, 2015Date of Patent: April 23, 2019Assignee: Osteofuse, Inc.Inventors: Melissa A. Kacena, Tien-Min Gabriel Chu
-
Patent number: 10265132Abstract: The present invention relates generally to methods of preparing antimicrobial elastomeric articles that include an elastomeric article having an antimicrobial coating provided thereon. The antimicrobial elastomeric articles exhibit enhanced ability to reduce or eliminate microbes that come in contact with the article. Certain aspects of the invention are further directed to methods of packaging the antimicrobial elastomeric articles, where the packaged antimicrobial articles exhibit antimicrobial effectiveness for an extended period of time as compared to unpackaged antimicrobial articles. Antimicrobial elastomeric articles and packaged antimicrobial elastomeric articles prepared in accordance with the methods of the present invention are also provided.Type: GrantFiled: June 14, 2016Date of Patent: April 23, 2019Assignee: ALLEGIANCE CORPORATIONInventors: Nicholas Ryan Krogman, Walter Harold Isaac, Katia Simeonov Petrov, Shiping Wang
-
Patent number: 10213433Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: November 10, 2014Date of Patent: February 26, 2019Assignee: AbbVie Inc.Inventors: Nathaniel Catron, David Lindley, Jonathan M. Miller, Eric A. Schmitt, Ping Tong
-
Patent number: 10207029Abstract: The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.Type: GrantFiled: April 1, 2015Date of Patent: February 19, 2019Assignee: KLOX TECHNOLOGIES INC.Inventors: Andreas Nikolis, Lise Hébert
-
Patent number: 10202479Abstract: Disclosed herein is a block copolymer comprising a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers; and a second block derived from an acrylate monomer. Disclosed herein too is a method comprising reacting a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers with an initiator to form a macroinitiator; and polymerizing a second block onto the first block to form a block copolymer; where the second block is derived by polymerizing an acrylate monomer; and where the block copolymer has a chi parameter of greater than or equal to about 0.05, when measured at a temperature of 200° C. to 210° C.; where the chi parameter is a measure of interactions between the first block and the second block of the copolymer.Type: GrantFiled: June 7, 2013Date of Patent: February 12, 2019Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, DOW GLOBAL TECHNOLOGIES LLCInventors: Phillip Dene Hustad, Frank Steven Bates, Marc Andrew Hillmyer, Justin Glenn Kennemur
-
Patent number: 10195153Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.Type: GrantFiled: August 12, 2014Date of Patent: February 5, 2019Assignee: Pharmaceutical Manufacturing Research Services, Inc.Inventors: Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny
-
Patent number: 10188593Abstract: Disclosed are: (a) controlled release matrix particles containing 10-70 wt. % of a hydrophobic active ingredient, 21-72 wt. % of a polysaccharide, 3.80-12 wt. % of a crosslinking agent, 1.00-6 wt. % of a catalyst and 0.10-5 wt. % of a silica flow aid; (b) controlled release core/shell particles containing 10-70 wt. % of a hydrophobic active ingredient, 1.0-3.2 wt. % of an epoxidized oil, 21-64 wt. % of a polysaccharide, 7.6-23% of an amine-functionality containing material, and 0.10-5 wt. % of a silica flow aid; and (c) hybrid particles wherein the core/shell particles are contained in a matrix. Also disclosed are methods for making the particles and compositions containing the particles.Type: GrantFiled: June 16, 2017Date of Patent: January 29, 2019Assignee: Spray-Tek, Inc.Inventors: Jiten Odhavji Dihora, Caroline Rachel Multari
-
Patent number: 10184027Abstract: The present invention relates to biodegradable polyesteramides (PEAs) comprising hydrophobic alpha-amino acids, diols, aliphatic dicarboxylic acids and optionally diamines whereby at least one of the dicarboxylic acids, diols or diamines comprises disulphide linkages. The present invention also relates to the use of the polyesteramides in medical applications such as cancer treatment, ophthalmic applications, therapeutic cardiovascular applications, veterinary applications, pain management applications, MSK applications and vaccine delivery compositions. The present invention also relates to a drug delivery composition comprising the PEA's and to a drug delivery system such as micro- or nanoparticles, micelles, liposomes, polymerosomes, micro- and nanogels, polymerosomes or nanotubes.Type: GrantFiled: August 10, 2015Date of Patent: January 22, 2019Assignee: DSM IP ASSETS, B.V.Inventors: Aylvin Jorge Angelo Athanasius Dias, Zhiyuan Zhong, Huanli Sun, Wei Wang, Fenghua Meng, Jan Feijen
-
Patent number: 10172852Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.Type: GrantFiled: July 24, 2015Date of Patent: January 8, 2019Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh Khopade, Arindam Halder
-
Patent number: 10154969Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.Type: GrantFiled: February 28, 2013Date of Patent: December 18, 2018Assignee: PIERRE FABRE MEDICAMENTInventors: Isabel Ribeiro Dos Santos, Michel Sournac
-
Patent number: 10155009Abstract: An object of the present invention is to provide a composition that serves as an efficient arginine substrate for inducible NO synthase (iNOS) in tumor. The present invention provides a polyion complex (PIC) of PEG-b-poly(L-Arg) or poly(L-Arg)-b-PEG-b-poly(L-Arg) and a polyanionic polymer, and use thereof.Type: GrantFiled: April 15, 2016Date of Patent: December 18, 2018Assignee: GENERAL INCORPORATED ASSOCIATION TSUKUBA GLOBAL INNOVATION PROMOTION AGENCYInventors: Yukio Nagasaki, Shinpei Kudo, Yuji Hiramatsu, Hiroaki Sakamoto, Quoc Thang Bui, Binh Long Vong
-
Patent number: 10105467Abstract: Biodegradable, bioabsorbable cross-linked polymer tissue scaffolds for filling a void in human or animal soft tissue, such as a surgical or other wound, are disclosed. Drugs incorporated into the polymer backbone and/or loaded into the matrix are released directly to the target site. Additional non-toxic chemical constituents can be used to tune the hydrophilio hydrophobic and other physical properties of the cross-linked polymer tissue scaffolds, and incorporating brominated or iodinated constituents provides radio-opacity. The radio-opaque cross-linked polymer tissue scaffolds can assist in the targeting of radiation therapy.Type: GrantFiled: January 22, 2014Date of Patent: October 23, 2018Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Joachim B. Kohn, Atif J. Khan, Nava Shpaisman
-
Patent number: 10099947Abstract: A water treatment solution may include a metal salt and a base product fluid. The base product fluid may include a molecular compound that is a chelating compound. The molecular compound may have the formula: ((NH4)2SO4)a.(H2SO4)b.(H2O)c.(NH4HSO4)x. In the formula, a may be between 1 and 5, b may be between 1 and 5, c may be between 1 and 5, and x may be between 1 and 10. The water treatment solution may be formed by adding the metal salt to the base product fluid and water. The water treatment solution may be added to water in need of treatment. The water in need of treatment may be a static body of water.Type: GrantFiled: June 16, 2016Date of Patent: October 16, 2018Assignee: Earth Science LaboratoriesInventors: David Nicholas, Reid Henry Bowman, David Hammond, Freddie L. Singleton
-
Patent number: 10087553Abstract: A polymer-micelle complex suitable for use as an aid to preparing fibers, particularly nanofibers, by electrospinning. The polymer-micelle complex may be designed to impart viscosity, surface tension and conductivity properties optimal for electrospinning. By incorporating the complex as a secondary ingredient, one may electrospin sparingly soluble or low molecular weight polymers. Moreover, the polymer-micelle complex can be used as a generic carrier for preparing fibers incorporating other desired materials, such as rigid or globular (hard-to-spin) polymers, enzymes, cells, viral particles and nanoparticles.Type: GrantFiled: April 12, 2018Date of Patent: October 2, 2018Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Ramanathan Nagarajan, Christopher P Drew, Charlene M Mello
-
Patent number: 10076526Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Type: GrantFiled: November 23, 2015Date of Patent: September 18, 2018Assignee: Allergan, Inc.Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
-
Patent number: 10052283Abstract: Disclosed is a composition for forming an injectable hydrogel. The composition includes 1% by weight or less of a graphene-based material and 5% by weight or more of a triblock copolymer. The triblock copolymer may be a copolymer represented by Formula 1: wherein n is an integer from 8 to 540, m is an integer from 16 to 70, and R is H or a vinylcarbonyl group (CH2?CHCO—). When R in Formula 1 is a vinylcarbonyl group, the triblock copolymer may be crosslinked through the vinylcarbonyl group to form a nanogel. The composition can be prepared by a simple mixing process. In addition, the composition is substantially free from in vitro and in vivo stability problems encountered with conventional hydrogel compositions. Furthermore, the composition has high biocompatibility as well as excellent mechanical properties such as high storage modulus.Type: GrantFiled: February 19, 2015Date of Patent: August 21, 2018Assignee: Gwangju Institute of Science and TechnologyInventors: Giyoong Tae, Da-ae Won
-
Patent number: 10052289Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.Type: GrantFiled: December 18, 2009Date of Patent: August 21, 2018Assignee: Flamel Ireland LimitedInventors: Rémi Meyrueix, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
-
Patent number: 10034834Abstract: The dermatological compositions deliver water and/or other hydrophilic compounds into or through the dermis using reverse micelles. The compositions include an oil-based continuous phase and an emulsifier that form nanoparticle micelles. The nanoparticle micelles are formulated into biocompatible topical ointments that are stable at room temperature and can be distributed in consumer packaging and consumer distribution channels.Type: GrantFiled: October 26, 2015Date of Patent: July 31, 2018Assignee: AQUA REGENERATIVE THERAPIES LLCInventor: Sean Matthew Anderson
-
Patent number: 10029081Abstract: A molding compact for forming a transdermal absorption sheet on which a needle-shaped protruding part is arranged is a molding compact that is a laminate of: a first member having a needle-shaped recessed part formed on a front surface thereof, the needle-shaped recessed part being an inverse of the needle-shaped protruding part; a second member provided on a back surface of the first member, the second member being composed of a waterproof and moisture-permeable material; and a third member provided on a back surface of the second member, the third member being composed of a rigid body. Provided are a molding compact that makes it possible to prevent leakage of a drug-containing solution filled into the needle-shaped recessed part, and a manufacturing method for a transdermal absorption sheet using the molding compact.Type: GrantFiled: May 12, 2015Date of Patent: July 24, 2018Assignee: FUJIFILM CorporationInventors: Yanlong Che, Takayoshi Oyamada, Junya Yoshida, Shotaro Ogawa
-
Patent number: 10022325Abstract: The present invention provides compositions and methods for the treatment of cancer are provided.Type: GrantFiled: March 4, 2013Date of Patent: July 17, 2018Assignee: Board of Regents of the University of NebraskaInventors: Alexander V. Kabanov, Daria Y. Alakhova, Yi Zhao
-
Patent number: 10016489Abstract: The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include temporary ALDH2 deficiency, such as that seen by alcohol poisoning or an ischemic event.Type: GrantFiled: April 23, 2014Date of Patent: July 10, 2018Inventor: Ilana Katsnelson
-
Patent number: 10010709Abstract: Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.Type: GrantFiled: December 16, 2010Date of Patent: July 3, 2018Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Daniel S. Kohane, Hila Epstein-Barash, Mark A. Borden
-
Patent number: 9950092Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.Type: GrantFiled: June 30, 2016Date of Patent: April 24, 2018Assignee: Allergan, Inc.Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis